The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial
This study aimed to evaluate the effects of autologous dendritic cell (DC) immunotherapy on clinical outcomes (glomerular filtration rate/GFR and urine creatinine albumin ratio/UACR) and endothelial dysfunction (ICAM, VCAM, VEGF) in patients with diabetic kidney disease (DKD). Endothelial dysfunctio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/1/31 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588791818223616 |
|---|---|
| author | Martina Lily Yana Enda Cindylosa Sitepu Jonny Linda Chiuman I Nyoman Ehrich Lister Terawan Agus Putranto |
| author_facet | Martina Lily Yana Enda Cindylosa Sitepu Jonny Linda Chiuman I Nyoman Ehrich Lister Terawan Agus Putranto |
| author_sort | Martina Lily Yana |
| collection | DOAJ |
| description | This study aimed to evaluate the effects of autologous dendritic cell (DC) immunotherapy on clinical outcomes (glomerular filtration rate/GFR and urine creatinine albumin ratio/UACR) and endothelial dysfunction (ICAM, VCAM, VEGF) in patients with diabetic kidney disease (DKD). Endothelial dysfunction induced by inflammation is one of the key factors in the pathogenesis of DKD. In this one-group pretest–posttest quasi-experimental study, 69 subjects with DKD were administered a single dose of autologous DC immunotherapy ex vivo. UACR was measured at baseline and at weeks 1, 2, 3, and 4, while ICAM, VCAM, VEGF, and GFR were measured at baseline and at week 4 post-immunotherapy. The results showed a significant reduction in median UACR from 250 (IQR 71–668) mg/g at baseline to 164 (IQR 49–576) mg/g at week 4 (<i>p</i> < 0.05). GFR did not show any significant changes after immunotherapy. HbA1c (B = −33.270, <i>p</i> = 0.021) and baseline UACR (B = −0.185, <i>p</i> < 0.001) were identified as significant predictors of UACR change. Although there were no significant changes in ICAM, VCAM, and VEGF, subgroup analysis revealed a decrease in VCAM in macroalbuminuria patients and an increase in those with good glycemic control, suggesting differing endothelial responses. In conclusion, autologous DC immunotherapy effectively reduced UACR in DKD patients, and significant VCAM changes were found in macroalbuminuria and good glycemic control subjects. Further research is needed to understand the mechanisms behind UACR reduction and the long-term impact of this therapy. |
| format | Article |
| id | doaj-art-b26d80b5a11f4290a157daf87521e8ca |
| institution | Kabale University |
| issn | 1467-3037 1467-3045 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj-art-b26d80b5a11f4290a157daf87521e8ca2025-01-24T13:27:27ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-01-014713110.3390/cimb47010031The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical TrialMartina Lily Yana0Enda Cindylosa Sitepu1Jonny2Linda Chiuman3I Nyoman Ehrich Lister4Terawan Agus Putranto5Indonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, IndonesiaIndonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, IndonesiaIndonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, IndonesiaFaculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, IndonesiaFaculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, IndonesiaIndonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, IndonesiaThis study aimed to evaluate the effects of autologous dendritic cell (DC) immunotherapy on clinical outcomes (glomerular filtration rate/GFR and urine creatinine albumin ratio/UACR) and endothelial dysfunction (ICAM, VCAM, VEGF) in patients with diabetic kidney disease (DKD). Endothelial dysfunction induced by inflammation is one of the key factors in the pathogenesis of DKD. In this one-group pretest–posttest quasi-experimental study, 69 subjects with DKD were administered a single dose of autologous DC immunotherapy ex vivo. UACR was measured at baseline and at weeks 1, 2, 3, and 4, while ICAM, VCAM, VEGF, and GFR were measured at baseline and at week 4 post-immunotherapy. The results showed a significant reduction in median UACR from 250 (IQR 71–668) mg/g at baseline to 164 (IQR 49–576) mg/g at week 4 (<i>p</i> < 0.05). GFR did not show any significant changes after immunotherapy. HbA1c (B = −33.270, <i>p</i> = 0.021) and baseline UACR (B = −0.185, <i>p</i> < 0.001) were identified as significant predictors of UACR change. Although there were no significant changes in ICAM, VCAM, and VEGF, subgroup analysis revealed a decrease in VCAM in macroalbuminuria patients and an increase in those with good glycemic control, suggesting differing endothelial responses. In conclusion, autologous DC immunotherapy effectively reduced UACR in DKD patients, and significant VCAM changes were found in macroalbuminuria and good glycemic control subjects. Further research is needed to understand the mechanisms behind UACR reduction and the long-term impact of this therapy.https://www.mdpi.com/1467-3045/47/1/31dendritic cellimmunotherapycell transferdiabetic kidney diseaseendothelial dysfunction |
| spellingShingle | Martina Lily Yana Enda Cindylosa Sitepu Jonny Linda Chiuman I Nyoman Ehrich Lister Terawan Agus Putranto The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial Current Issues in Molecular Biology dendritic cell immunotherapy cell transfer diabetic kidney disease endothelial dysfunction |
| title | The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial |
| title_full | The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial |
| title_fullStr | The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial |
| title_full_unstemmed | The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial |
| title_short | The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial |
| title_sort | effect of autologous dendritic cell immunotherapy on kidney function and endothelial dysfunction of patients with diabetic kidney disease dkd an open label clinical trial |
| topic | dendritic cell immunotherapy cell transfer diabetic kidney disease endothelial dysfunction |
| url | https://www.mdpi.com/1467-3045/47/1/31 |
| work_keys_str_mv | AT martinalilyyana theeffectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT endacindylosasitepu theeffectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT jonny theeffectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT lindachiuman theeffectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT inyomanehrichlister theeffectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT terawanagusputranto theeffectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT martinalilyyana effectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT endacindylosasitepu effectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT jonny effectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT lindachiuman effectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT inyomanehrichlister effectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial AT terawanagusputranto effectofautologousdendriticcellimmunotherapyonkidneyfunctionandendothelialdysfunctionofpatientswithdiabetickidneydiseasedkdanopenlabelclinicaltrial |